Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial
1. 请及时下载文件确认是否正确, 系统将在 2026-03-11 14:32:06 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
J Lin, Y Huang, B Xu, X Gu, J Huang, J Sun, L Jia, J He…
Bmj, 2025
bmj.com
Objective To assess the efficacy and safety of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in participants with metabolic dysfunction-associated steatohepatitis (MASH). Design Multicentre, double blind, randomised, placebo controlled trial. Setting Six tertiary hospitals in China from 23 November 2018 to 28 March 2023. Participants 154 adults with biopsy diagnosed MASH, with or without type 2 diabetes. Interventions All participants were randomly assigned to receive 10 mg orally of dapagliflozin or matching placebo once daily …
